Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Maintenance Kidney Transplant
Conditions
Maintenance Kidney Transplant
Trial Timeline
Jul 1, 2006 → Sep 1, 2008
NCT ID
NCT00400647About Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil
Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil is a approved stage product being developed by Novartis for Maintenance Kidney Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT00400647. Target conditions include Maintenance Kidney Transplant.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00400647 | Approved | Completed |
Competing Products
20 competing products in Maintenance Kidney Transplant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2422347 + placebo | Eli Lilly | Phase 2 | 52 |
| LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - Capsule | Eli Lilly | Phase 1 | 33 |
| Zolpidem MR + Estazolam | Astellas Pharma | Approved | 85 |
| zolpidem MR + nitrazepam + placebo | Astellas Pharma | Phase 3 | 77 |
| FK199B + Zolpidem | Astellas Pharma | Phase 3 | 77 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Graceptor® | Astellas Pharma | Pre-clinical | 23 |
| Zolpidem MR + Zolpidem IR | Astellas Pharma | Approved | 85 |
| Zolpidem MR + Zolpidem | Astellas Pharma | Phase 3 | 77 |
| Lemborexant | Eisai | Phase 2 | 52 |
| Lemborexant + Placebo | Eisai | Phase 3 | 77 |
| Lemborexant | Eisai | Pre-clinical | 23 |
| Eszopiclone + Fluoxetine + Placebo | Sumitomo Pharma | Approved | 85 |
| Org 50081 + Org 50081 + Placebo + zopiclone | Merck | Phase 1 | 33 |
| esmirtazapine | Merck | Phase 3 | 77 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Esmirtazapine + Placebo | Merck | Phase 3 | 77 |
| Cyclosporine - cyclosporine microemulsion | Novartis | Approved | 85 |
| Enteric-coated Mycophenolate sodium (EC-MPS) | Novartis | Approved | 85 |